血脂康对慢性心力衰竭患者心功能、血清C-反应蛋白和血脂的影响

目的探讨血脂康对慢性心力衰竭（CHF）患者心功能和血清C-反应蛋白（CRP）的影响。方法68例患者随机分为两组，对照组（30例）应用血管紧张素转换酶抑制剂、B受体阻滞剂、利尿剂和洋地黄制剂治疗，血脂康组（38例）在对照组基础上加用血脂康治疗0．5年，治疗前后采用超声心动图和酶联免疫法分别测定心功能和CRP水平。结果（1）NYHA心功能分级、左室舒张期末内径和左室收缩期末内径治疗后两组均显著下降（P〈0．05），且血脂康组显著低于对照组（P〈0．05）；左室射血分数和E／A峰比值显著上升（P〈0．05），且血脂康组显著高于对照组（P〈0．05）。（2）CRP：治疗后血脂康组较治疗前显著降低（P〈0．01），且显著低于对照组（P〈0．05）；对照组治疗前后比较差异无显著性。结论血脂康在改善心功能的同时能降低血清CRP水平。

Effect of Xuezhikang on Cardiac Function,Serum C-reactive Protein and Blood Lipid in Patients with Chronic Heart Failure

OBJECTIVE: To evaluate the effect of Xuezhikang (XZK) on cardiac function and serum C-reactive protein (CRP) in patients with chronic heart failure (CHF). METHODS: Sixty-eight CHF patients were randomly assigned to two groups, the control group (30 cases) treated with angiotensin converting enzyme inhibitor, beta-receptor inhibitor, digoxin and diuretic, and the treated group (38 cases) with the above treatment plus XZK for six months. The changes of cardiac function and serum CRP level were measured by echocardiography and enzyme-linked immunosorbent assay (ELISA) respectively before and after treatment. RESULTS: Compared with those before treatment, the NYHA cardiac function grade, the left ventricular dimension end diastole (LVDd), and the left ventricular dimension end systole (LVDs) decreased significantly (P < 0.05), and the ejection fraction (EF) and E/A ratio increased significantly in both groups after treatment (P < 0.05) , however, the decrement or increment was more significant in the treated group than that in the control group respectively (P < 0.05); the serum CRP level decreased significantly in the treated group after treatment and showed a level obviously lower than that in the control group (P < 0.05), which changed insignificantly after treatment. CONCLUSION: Xuezhikang could improve cardiac function and decrease serum CRP level at the same time.